It was reported yesterday that United States-based CASI Pharmaceuticals has signed a license agreement for exclusive worldwide rights to the investigational anti-CD38 monoclonal antibody TSK011010 programme from Black Belt Therapeutics.
According to the terms of the contract, CASI Pharmaceuticals has received global rights to TSK011010 for an upfront payment of EUR5m and an equity investment of EUR2m, along with certain milestone and royalty payments.
The equity investment will be made in a newly established company of Black Belt Therapeutics concentrating on novel immuno-oncology targets. CASI will be responsible for all development and commercialisation activities of the TSK011010 programme.
The product is at the IND/IMPD submission stage of development, with Phase one trials expected to start in late 2019/early 2020. Preclinical data indicates that the product is to have improved activity against a broad array of malignancies that express CD38 and potentially better safety compared to other CD38 Mabs.
ChemDiv extends CMC services collaboration supporting clinical development of ratutrelvir
NeuroKaire and Compass Pathways partner to advance AI-driven research in psychedelic psychiatry
BioArctic reports third-quarter royalties from Leqembi sales
GenSight Biologics secures FDA authorisation for expanded access to GS010/LUMEVOQ in the US
AnHorn Medicines reports positive results from US Phase I trial of AH-001
ArkBio commences Phase II clinical trial of AK0610
Curasight advances Phase 2 prostate cancer trial with Curium partnership
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Hemogenyx Pharmaceuticals advances HG-CT-1 trial and opens paediatric recruitment